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Background
Cancer cells disseminate and lodge in target organs, 
producing a distinct and mostly predictable pattern of 
metastasis [1,2]. Metastatic cells may evolve in the primary 
tumor but also, following dissemination, at distant sites 
[1]. Numerous genes favoring or suppressing the multiple 
metastatic steps have been identiﬁ   ed [1,2]. Moreover, 
primary tumor gene expression proﬁ  les  revealed 
signatures that can predict poor treatment outcomes, most 
probably linked to metastasis develop  ment [3].
In spite of the progress, however, due to important 
confounding factors, the dynamics driving the emergence 
of metastatic variants in patients is poorly understood. 
First, patients presenting with non-invasive lesions (that 
is, ductal carcinoma in situ) already have disseminated 
tumor cells [1,4]. Second, the metastatic phenotype can 
be acquired in parallel in the primary lesion and in the 
organ-lodged disseminated tumor cells, and the latter 
may evolve after primary tumor surgery and without 
development of local recurrences [1]. Th  ird, metastasis 
development can be remarkably delayed – suggesting 
that, before resuming growth and evolution, the lodged 
disseminated tumor cells (minimal residual disease) can 
remain dormant [5]. In a recent study, Kim and colleagues 
propose that the ability of circulating tumor cells (CTCs) 
to return to and grow in the primary tumor might aid in 
selecting the seeds of metastasis [6].
Article
Kim and colleagues at the Memorial Sloan Kettering 
Cancer Center asked whether CTCs could reseed a 
primary tumor [6]. Furthermore, they tested whether this 
reseeding selects for variants endowed with speciﬁ  c 
genes driving metastasis.
Th   e authors tagged breast and melanoma cell lines with 
ﬂ  uorescent proteins and/or luciferase. Th  e  MDA-MB-231 
human breast carcinoma cell line (MDA231) and its 
variant, selected via intravenous inoculations for 
enhanced lung colony formation (MDA231-LM2) [7], 
were primarily used in reseeding or cross-seeding 
experiments. Tagged and untagged tumor cells were 
injected separately into orthotopic contralateral sites. 
MDA231-LM2 cells were highly eﬃ   cient in disseminating 
and self-seeding a contralateral MDA231-LM2 or 
MDA231 mass or in cross-seeding breast MCF7 or 
melanoma A375 tumors. Similarly, MDA231-LM2 lung 
colonies produced by intravenous injection also seeded
orthotopically growing MDA231 tumors. Th  us, 
regardless of their growth location, the MDA231-LM2 
cells can seed an established tumor mass.
Curiously, MDA231-LM2 cells were not reported to 
spontaneously seed lungs from the primary tumor. Th  is 
suggests that spontaneous seeding of a tumor mass is less 
restrictive than seeding of target organs. Alternatively, 
enhanced lung colonization selected through forced 
intra  venous inoculation [7] might exacerbate cell traits 
that do not entirely recapitulate organ-speciﬁ  c metastasis.
In an important experiment, MDA231 cells that spon-
taneously seeded the same contralateral tumor were 
enriched (MDA231-S1a). Upon reinjection through 
diﬀ  erent routes, MDA231-S1a cells spontaneously seeded 
a contralateral tumor, but apparently not lungs or other 
organs. Only after direct injection into the bloodstream 
did they seed bones, brain, or lungs. IL-6 and IL-8 
produced by contralateral human tumors served as CTC 
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© 2010 BioMed Central Ltdattractants, and this might explain the preferred 
spontaneous tumor versus lung targeting. Th  e role of 
human tumor versus mouse lung-derived cytokines 
directing this tropism, however, cannot be ruled out. 
MMP1, FASCIN1 and CXCL1 genes required here for 
tumor seeding are also part of a human breast cancer 
signature associated with metastasis development [7]. 
Further, stromal cells aided self-seeders and the latter 
cells also accelerated primary tumor growth.
Th  e  identiﬁ  ed genes or the stromal cell involvement are 
not entirely new to metastatic progression [2,8-11]. All 
organ-speciﬁ  c metastasis genes being represented in the 
MDA231-S1a derivate, however, was a surprising 
observation. Possibly only few of these genes are required 
for tumor mass colonization, and the additional organ-
speciﬁ  c genes are enriched because they facilitate but are 
not required for self-seeding. Alternatively, the 
contralateral tumor mimics a multiorgan microenviron-
ment favoring selection of all variants simultaneously.
Overall, these studies show that important information 
on the mechanisms contributing to target organ 
colonization can be drawn from self-seeding or cross-
seeding experimental models.
Viewpoint
Is there any parallel between these experiments and 
metastasis in patients, and what clinical scenarios could 
be envisioned for such a process? Th  ese experiments 
possibly model a rare phenomenon in patients where one 
malignant tumor (for example, prostate or breast carci-
noma) metastasizes to a diﬀ  erent second primary tumor, 
usually a benign lesion [12-14]. Th  ese are exceedingly 
rare cases even in the 2 to 3% of patients that develop two 
diﬀ   erent cancers simultaneously. Kim and colleagues’ 
study shows that, as in these rare cases, malignant cells 
will metastasize to a second tumor if available. In these 
patients, however, cross-seeding was simultaneous with 
multiple organ metastasis [14].
Self-seeding and the presence of a tumor mass may not 
be a sine qua non requisite because metastasis develops 
in patients after undergoing surgery (the majority) for 
small or larger invasive lesions, such as in breast cancer. 
If tumor masses are required [6], self-seeding would not 
select for metastatic variants during periods of minimal 
residual disease or favor local recurrences, unless local 
microscopic residual disease or a remaining reactive 
stroma is suﬃ     cient to fuel this process. Self-seeding, 
however, may occur in patients with inoperable primaries 
and metastases or in those that, after primary tumor 
surgery, still carry multiple metastases and may have a 
constant CTC population. Finally, the timing of meta-
stasis must be considered. Why in some patients does it 
take 1 or 2 years but in other patients 10 years or more 
for the metastatic variants carrying the poor prognosis 
genes [3,7] to grow into overt metastasis? Does this mean 
that the time to overt metastasis is regulated by other 
mechanisms and that self-seeding or cross-seeding is 
only relevant between established metastasis [15]? Th  ese 
and many other questions generated by this thought-
provoking study will surely fertilize the ﬁ  eld of metastasis 
to provide a clearer view on how to target this lethal step 
of cancer progression.
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